ETON PHARMACEUTCIALS INC (ETON)
Health Care · Specialty Pharmaceuticals · NASDAQ
Eton Pharmaceuticals is a specialty drug company dedicated to acquiring and commercializing a diverse portfolio of therapies for rare diseases.
What ETON PHARMACEUTCIALS INC does
Eton Pharmaceuticals is an innovative pharmaceutical company focused on the development and commercialization of treatments for rare diseases. The company maintains a portfolio of commercial rare disease products and several candidates in late-stage development. Its business model involves acquiring and commercializing specialty pharmaceutical assets.
Themes: rare diseases, orphan drugs, pharmaceutical commercialization
Fundamentals
- Price$49.30 as of 2026-10-21 close
- Market cap$1.4B as of 2026-08-11 (share count; price 2026-10-21)
- 1-year return+165.8% 2025-10-21 close $18.55 → 2026-10-21 close $49.30
- P/En/a negative earnings
- Net margin-5.8% FY2025, SEC XBRL
- Gross margin+53.5% FY2025, SEC XBRL
- ROE-17.6% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.60 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+104.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+55.5% SEC XBRL
- Beta0.82 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How ETON compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $38M | $25M | $13M | $12M | $7M† | -$5000† |
| Q1 FY2026 2026-03-31 | $24M | $15M | $2M | $2M | $7M | $75000 |
| Q4 FY2025 2025-12-31 | $21M† | $13M† | $2M† | $1M† | -$12M† | $49000† |
| Q3 FY2025 2025-09-30 | $22M | $8M | -$1M | -$2M | $12M† | $284000† |
| Q2 FY2025 2025-06-30 | $19M | $12M | -$1M | -$3M | $8M† | $0† |
| Q1 FY2025 2025-03-31 | $17M | $10M | -$470000 | -$2M | $2M | $0 |
| Q4 FY2024 2024-12-31 | $12M† | $6M† | $629000† | -$598000† | -$765000† | $12000† |
| Q3 FY2024 2024-09-30 | $10M | $6M | $509000 | $627000 | $3M† | $0† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$27M
- Total debt$28M borrowings only; leases excluded
- Net debt$1M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How ETON PHARMACEUTCIALS INC looks technically
ETON PHARMACEUTCIALS INC (ETON) is trading 43.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 145 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 25.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 43.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +43.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $56.58 | $56.58 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $34.27 | $34.27 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 57. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 145 trading days ago — a "golden cross", a bullish long-term signal | 145 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control | 26.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 36.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($48.36 to $57.00) — its "stochastic" reading is 11 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 10.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 37 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $66.37 | $66.37 |
|---|---|---|
| From the 52-week high | it is 25.7% below its 52-week high (its highest price of the past year) | -25.7% |
| Above the 52-week low | it is 245.5% above its 52-week low (its lowest price of the past year) | +245.5% |
| Below the 52-week high | it is 25.7% below its highest point of the past year | 25.7% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 42 trading days ago | 42 sessions |
| All-time high | its highest closing price on record is $66.37 (set on 2026-08-24) | $66.37 |
| Given back of the 52-week move | over the past year its closes ranged ($14.35 to $64.43), and it has given back roughly a third of its rise from last year’s low — 30% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $31.88 to $33.48. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.2% |
| From the all-time high | it is 25.7% below its all-time high | -25.7% |
| Nearest price level | it is trading 59.4% above a support level at $20.01 — a price it turned at twice since 2025-11-06, most recently on 2026-02-25. Since 2024-10-21 it has 10 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -59.4% |
| All-time low | its lowest closing price on record is $1.95 (set on 2022-09-23) | $1.95 |
| Above the all-time low | it is 2428.2% above its all-time low | +2,428% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 35th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.99 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.99 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $47.76 and $60.38 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $47.76 – $54.07 – $60.38 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 5.0 daily ranges above its 200-day average price (43.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.56× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-10-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Open gap | it gapped 34.6% above the previous close 47 sessions ago and has not traded back through the level it left behind at 40.8 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +34.6% |
| Gap filled | a 2.5% gap down opened on 2026-10-01 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 14 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.8 percentage points (the stock lost 10.9% while the market lost 0.1%) | -10.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 10.8 percentage points (the stock gained 14.1% while the market gained 3.3%) | +10.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 99.6 percentage points (the stock gained 109.4% while the market gained 9.8%) | +99.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 150.6 percentage points (the stock gained 165.8% while the market gained 15.2%) | +150.6% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -2.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $38.70 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | +27.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $57.03 — a volume-weighted average of daily closes over 49 sessions, not a true tick-by-tick VWAP. | -13.6% |
Price levels it has turned at before
ETON last closed at $49.30 on 2026-10-21. Since 2024-10-21 it has turned at 10 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $20.01 | Support | 59.4% below the last close | turned there twice · 2025-11-06 to 2026-02-25 |
| $18.36 | Support | 62.8% below the last close | turned there twice · 2025-02-05 to 2025-09-05 |
| $17.54 | Support | 64.4% below the last close | turned there twice · 2025-08-11 to 2025-10-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $57.00.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $37.89 and $45.19 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $57.00.
This reading has stood for 3 trading days, since 2026-10-19.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$71.00 range $68.00 – $76.00; median $70.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ETON
- Consensus EPS estimate$0.37 next reporting period, as of 2026-10-15
- Estimate change, 30 days$0.00 (0.0%) from $0.37, on 2026-09-10, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on successful commercialization of rare disease product portfolio and late-stage candidates.","Exposure to regulatory and FDA approval processes, including potential changes to orphan drug fee exemptions.","Risks associated with the integration of acquired pharmaceutical assets and rights."]
What changed in the latest 10-Q
AI-assisted comparison of ETON's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing states the company has eleven commercial rare disease products, adding IMPAVIDO® and noting IMPAVIDO® is scheduled for commercialization in September 2026.
- Newer filing includes three-month and six-month results for periods ended June 30, 2026 and June 30, 2025, including revenue, gross profit, licensing revenue, R&D expense, and G&A expense figures.
- Newer filing states the six-month 2026 revenue increase was driven by increased sales of INCRELEX®, GALZIN®, ALKINDI SPRINKLE®, Carglumic Acid and the addition of HEMANGEOL® product sales.
- Newer filing states licensing revenue for the six months ended June 30, 2026 was $0 compared to $3,286 for the same period in 2025.
- Newer filing states that in 2025 the Company paid a $2,155 NDA filing fee for DESMODA™, which was approved by the FDA in February of 2026.
- Newer filing includes as of June 30, 2026 total assets of $115.8 million, cash and cash equivalents of $26.8 million, and working capital of $23.5 million.
- Newer filing includes a cash flow table for the six-month periods ended June 30, 2026 and 2025.
- Newer filing states net cash from operating activities for the six months ended June 30, 2026 was $14,660, net cash used in investing activities was $15,070, and net cash from financing activities was $1,313, with change in cash and cash equivalents of $903.
- Newer filing states the increase in net cash from financing activities related to increased proceeds of $3,649 from stock option exercises, proceeds of $270 from the employee stock purchase program, partially offset by a $3,000 principal debt payment.
- Removed:
- Older filing stated the company has ten commercial rare disease products, without including IMPAVIDO®.
- Older filing included three-month results for periods ended March 31, 2026 and March 31, 2025, including revenue, gross profit, licensing revenue, R&D expense, and G&A expense figures.
- Older filing stated the three-month 2026 revenue increase was driven by increased sales of INCRELEX®, GALZIN®, ALKINDI SPRINKLE®, and Carglumic Acid, and the addition of KHINDIVI™ sales.
- Older filing stated licensing revenue for the three months ended March 31, 2026 was zero compared to $3,286 for the same period in 2025.
- Older filing stated the increase in R&D expenses for the three months ended March 31, 2026 was primarily due to higher clinical study expenses associated with KHINDIVI™ label expansion and increased expenses associated with ET-700 project development activities.
- Older filing included as of March 31, 2026 total assets of $97.7 million, cash and cash equivalents of $19.7 million, and working capital of $9.1 million.
- Older filing included a cash flow table for the three-month periods ended March 31, 2026 and 2025.
- Older filing stated net cash from operating activities for the three months ended March 31, 2026 was $7,405, net cash used in investing activities was $15,075, and net cash from financing activities was $1,389, with change in cash and cash equivalents of $(6,281).
- Older filing stated the increase in net cash from financing activities related to increased proceeds from stock option exercises.
- Reworded:
- Overview product count changed from ten commercial rare disease products (older) to eleven, with IMPAVIDO® added and scheduled for commercialization in September 2026 in the newer filing.
- Results of Operations period changed from three months ended March 31, 2026/2025 (older) to three and six months ended June 30, 2026/2025 (newer).
- Description of revenue increase drivers changed from three-month comparison mentioning KHINDIVI™ (older) to six-month comparison mentioning ALKINDI SPRINKLE® and HEMANGEOL® (newer).
- Licensing revenue comparison changed from three-month figures (older) to six-month figures (newer).
- R&D expense explanation changed from three-month period with KHINDIVI™ and ET-700 reasons (older) to three-month and six-month figures mentioning the 2025 DESMODA™ NDA filing fee and FDA approval in February 2026 (newer).
- G&A expense figures changed from three-month periods ended March 31, 2026 and 2025 (older) to three-month and six-month periods ended June 30, 2026 and 2025 (newer).
- Liquidity and Capital Resources balance sheet date changed from March 31, 2026 (older) to June 30, 2026 (newer).
- Cash flow table period changed from three-month periods ended March 31, 2026 and 2025 (older) to six-month periods ended June 30, 2026 and 2025 (newer).
- Investing activities explanation changed period from three months (older) to six months (newer), with wording 'also in February 2026' changed to 'which also occurred in February 2026'.
- Cash from financing activities explanation expanded from stock option exercises only (older) to include employee stock purchase program and principal debt payment (newer).
- Older filing had an additional sentence in the Non-GAAP Financial Measures section stating that these non-GAAP measures are among indicators management uses for planning and forecasting and should be considered in addition to GAAP; this sentence appears absent in the newer text excerpt.
- Notes:
- The newer filing excerpt appears truncated at the end of the Non-GAAP Financial Measures section; the older filing includes a reconciliation table and additional commentary not present in the provided newer text, so changes after the truncation point cannot be assessed.
Risk Factors
- Added:
- Newer filing (2026-08-13) adds disclosure under Item 2 that during the quarter ended June 30, 2026, the Company issued 296,215 shares of common stock at a weighted average exercise price of $31.83 through cashless exercise of 62,901 surrendered warrants, with no cash proceeds received, in reliance on Section 4(a)(2) of the Securities Act.
- Newer filing (2026-08-13) lists Exhibit 10.1: Sixth Amendment to Credit Agreement by and among the Company and SWK Funding LLC dated as of April 6, 2026.
- Newer filing (2026-08-13) lists Exhibit 10.2: Asset Purchase Agreement dated May 18, 2026 by and among Knight Therapeutics Europe S.A. and the Registrant (redacted).
- Newer filing (2026-08-13) lists Exhibit 10.3: Offer Letter Agreement by and between the Registrant and Judith Matthews, dated as of June 3, 2026.
- Newer filing (2026-08-13) signature block lists Judith M. Matthews as Chief Financial Officer (Principal Financial Officer).
- Removed:
- Older filing (2026-05-14) stated Item 2 Unregistered Sales of Equity Securities and Use of Proceeds was 'Not applicable.'
- Older filing (2026-05-14) listed Exhibit 10.1: Asset Purchase Agreement dated February 27, 2026 by and among Pierre Fabre Medicament Sas and the Registrant (redacted).
- Older filing (2026-05-14) signature block listed James R. Gruber as Chief Financial Officer (Principal Financial Officer).
- Reworded:
- Newer filing (2026-08-13) changes Item 5 disclosure to reference the three-month period ended June 30, 2026 instead of the three-month period ended March 31, 2026 in the older filing (2026-05-14).
- Newer filing (2026-08-13) references 'our 2025 10-K' risk factors in the introductory text, whereas the older filing (2026-05-14) also references 'our 2025 10-K' - both texts are identical in this regard.
- Newer filing (2026-08-13) replaces the previous Chief Financial Officer signatory James R. Gruber with Judith M. Matthews.
- Notes:
- The provided 'Risk Factors' section excerpts include Items 2-6, Exhibit Index, and Signatures rather than substantive risk factor text, limiting comparison of risk factor content.
- The introductory risk factor paragraphs appear identical between the two filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 12 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 1 sell ($229406) — 1 selling insider
- Last 90 days · read to 2026-10-160 buys · 12 sells ($14M) — 3 selling insiders
- Last 180 days · read to 2026-10-160 buys · 29 sells ($29M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-06. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ETON's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ETON as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,822,782
- Reported value $102,184,697
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ETON's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ETON had 1,834,090 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
ETON had 6.42% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.94 days to cover at the same settlement.
- Reported short interest (shares) 1,834,090
- Short interest (% of shares outstanding) 6.42%
- Prior settlement (shares) 1,542,982
- Reported change 18.87%
- Days to cover (reported) 2.94
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Horizon Therapeutics (Amgen)
- BioMarin Pharmaceutical (BMRN)
- Sarepta Therapeutics (SRPT)
- Alexion Pharmaceuticals (AstraZeneca)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ETON vs…
ETON PHARMACEUTCIALS INC is found in…
ETON ranks in…
Frequently asked questions
What does ETON PHARMACEUTCIALS INC (ETON) do?
Eton Pharmaceuticals is an innovative pharmaceutical company focused on the development and commercialization of treatments for rare diseases. The company maintains a portfolio of commercial rare disease products and several candidates in late-stage development. Its business model involves acquiring and commercializing specialty pharmaceutical assets.
What sector is ETON PHARMACEUTCIALS INC (ETON) in?
ETON PHARMACEUTCIALS INC (ETON) is classified in the Health Care sector. Its industry is Specialty Pharmaceuticals. It trades on NASDAQ.
Who are ETON PHARMACEUTCIALS INC's (ETON) competitors?
Notable peers of ETON PHARMACEUTCIALS INC (ETON) include Horizon Therapeutics (Amgen), BioMarin Pharmaceutical, Sarepta Therapeutics and Alexion Pharmaceuticals (AstraZeneca). This peer set is informational only — not financial advice.
Is ETON PHARMACEUTCIALS INC (ETON) overbought or oversold right now?
ETON PHARMACEUTCIALS INC (ETON) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ETON come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.